Keyphrases
Assessment Development
28%
Botulinum Neurotoxin (BoNT)
42%
Capsaicin
28%
Clinical Standards
14%
Clinical Trials
14%
Diagnostic Criteria
14%
Drug Response
14%
Drug Treatment
28%
Duloxetine
14%
Evaluation Assessment
28%
Evidence Evaluation
14%
Evidence-based Recommendations
14%
Extended Release
14%
Fixed Effects
14%
Gabapentin
42%
Grading of Recommendations
28%
High Concentration
28%
International Association for the Study of Pain
28%
Lack of Response
14%
Lidocaine Patch
42%
Mantel-Haenszel Method
14%
Meta-analysis
100%
Neuropathic Pain
100%
New Drugs
14%
Number-needed-to-treat
28%
Overstatement
14%
Pain Relief
14%
Peer-reviewed Journals
28%
Peripheral Neuropathic Pain
14%
Pharmaceutical Companies
14%
Pharmacological Treatment
14%
Pharmacotherapy
100%
Phenotypic Profiling
14%
Placebo Response
14%
Pregabalin
28%
Publication Analysis
14%
Publication Bias
28%
Randomized Double-blind Study
14%
Recommendations for Practice
42%
Serotonin-noradrenaline Reuptake Inhibitor
28%
Special Interest Groups
14%
Strong Opioids
28%
Systematic Meta-analysis
100%
Tolerability
14%
Topical Agents
14%
Topical Therapy
14%
Tramadol
42%
Treatment Effect
14%
Trial Outcomes
28%
Tricyclic Antidepressants
42%
Unmet Needs
14%
Medicine and Dentistry
Analgesia
12%
Botulinum Toxin A
37%
Capsaicin
25%
Clinical Trial
12%
Drug Therapy
100%
Duloxetine
12%
Gabapentin
37%
Health Care Cost
12%
Lidocaine
37%
Mantel Haenszel Test
12%
Meta-Analysis
100%
Neuropathic Pain
100%
Norepinephrine Reuptake Inhibitor
25%
Numbers Needed to Treat
25%
Placebo Effect
12%
Pregabalin
25%
Serotonin
25%
Systematic Review
100%
Topical Agent
25%
Tramadol
37%
Treatment Effect
12%
Tricyclic Antidepressant
37%
Pharmacology, Toxicology and Pharmaceutical Science
Botulinum Toxin A
37%
Capsaicin
25%
Clinical Trial
12%
Duloxetine
12%
Gabapentin
37%
Lidocaine
37%
Neuropathic Pain
100%
Norepinephrine Reuptake Inhibitor
25%
Number Needed to Treat
25%
Pharmacotherapy
100%
Placebo
12%
Pregabalin
25%
Serotonin
25%
Tolerability
12%
Topical Agent
25%
Tramadol
37%
Tricyclic Antidepressant
37%